세계의 자가면역질환 진단 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Autoimmune Disease Diagnostics Market size is anticipated to grow from USD 6.16 Billion in 2024 to USD 13.97 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 9.54% during the forecast period of 2026 to 2033.

The autoimmune disease diagnostics market is poised for significant growth, driven by the increasing prevalence of autoimmune disorders and advancements in diagnostic technologies. As awareness of autoimmune diseases rises, healthcare providers are increasingly focusing on early detection and accurate diagnosis to improve patient outcomes. Innovations in laboratory techniques, such as enzyme-linked immunosorbent assays (ELISA), multiplex assays, and next-generation sequencing, are enhancing the sensitivity and specificity of diagnostic tests. These advancements enable clinicians to identify a wide range of autoimmune conditions, including rheumatoid arthritis, lupus, and multiple sclerosis, facilitating timely and effective treatment strategies.

Moreover, the growing emphasis on personalized medicine is influencing the autoimmune disease diagnostics market. Tailoring treatment plans based on individual patient profiles and genetic markers is becoming increasingly feasible, allowing for more effective and targeted interventions. The integration of artificial intelligence and machine learning in diagnostic processes is also gaining traction, as these technologies can analyze complex data sets to identify patterns and predict disease progression. This shift towards data-driven diagnostics is expected to enhance the accuracy of autoimmune disease detection and improve patient management.

Additionally, the rise of point-of-care testing is transforming the landscape of autoimmune diagnostics. Rapid and convenient testing options are becoming essential in clinical settings, enabling healthcare providers to make informed decisions quickly. This trend is particularly relevant in remote and underserved areas, where access to specialized diagnostic facilities may be limited. In summary, the autoimmune disease diagnostics market is set for robust growth, characterized by technological innovation, personalized approaches, and a commitment to improving patient care in the face of complex autoimmune conditions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Product

• Consumables & Assay Kits
• Instruments

By Test Type

• Routine Laboratory Tests
• Inflammatory Markers
• Autoantibodies & Immunologic Test
• Other

By Disease

• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Sjogren's Syndrome
• Thyroiditis
• Scleroderma
• Other

By End User

• Clinical Laboratories
• Hospitals
• Other
• COMPANIES PROFILED
• Thermo Fisher Scientific
• Siemens
• Abbott
• Danaher
• Bio-Rad Laboratories
• Grifols
• Trinity Biotech
• Werfen
• HYCOR Biomedical
• EUROIMMUN AG
• Oncimmune
• HTG Molecular Diagnostics
• Seramun Diagnostica GmbH
• Exagen Inc.
• Cambridge Life Sciences Limited
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. AUTOIMMUNE DISEASE DIAGNOSTICS INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porters Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Test Type
  • 3.7.3 Market Attractiveness Analysis By Disease
  • 3.7.4 Market Attractiveness Analysis By End User
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data Analysis By Product
• 5.3. Consumables & Assay Kits Historic and Forecast Sales By Regions
• 5.4. Instruments Historic and Forecast Sales By Regions

6. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS BY TEST TYPE

• 6.1. Overview By Test Type
• 6.2. Historical and Forecast Data Analysis By Test Type
• 6.3. Routine Laboratory Tests Historic and Forecast Sales By Regions
• 6.4. Inflammatory Markers Historic and Forecast Sales By Regions
• 6.5. Autoantibodies & Immunologic Test Historic and Forecast Sales By Regions
• 6.6. Other Historic and Forecast Sales By Regions

7. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS BY DISEASE

• 7.1. Overview By Disease
• 7.2. Historical and Forecast Data Analysis By Disease
• 7.3. Rheumatoid Arthritis Historic and Forecast Sales By Regions
• 7.4. Systemic Lupus Erythematosus Historic and Forecast Sales By Regions
• 7.5. Sjögrens Syndrome Historic and Forecast Sales By Regions
• 7.6. Thyroiditis Historic and Forecast Sales By Regions
• 7.7. Scleroderma Historic and Forecast Sales By Regions
• 7.8. Other Historic and Forecast Sales By Regions

8. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS BY END USER

• 8.1. Overview By End User
• 8.2. Historical and Forecast Data Analysis By End User
• 8.3. Clinical Laboratories Historic and Forecast Sales By Regions
• 8.4. Hospitals Historic and Forecast Sales By Regions
• 8.5. Other Historic and Forecast Sales By Regions

9. GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE AUTOIMMUNE DISEASE DIAGNOSTICS COMPANIES

• 10.1. Autoimmune Disease Diagnostics Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF AUTOIMMUNE DISEASE DIAGNOSTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Thermo Fisher Scientific
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Siemens
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Abbott
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Danaher
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Bio-Rad Laboratories
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Grifols
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Trinity Biotech
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Werfen
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. HYCOR Biomedical
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. EUROIMMUN AG
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Oncimmune
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. HTG Molecular Diagnostics
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments
• 11.15. Seramun Diagnostica GmbH
  • 11.15.1 Company Overview
  • 11.15.2 Company Revenue
  • 11.15.3 Products
  • 11.15.4 Recent Developments
• 11.16. Exagen Inc.
  • 11.16.1 Company Overview
  • 11.16.2 Company Revenue
  • 11.16.3 Products
  • 11.16.4 Recent Developments
• 11.17. Cambridge Life Sciences Limited
  • 11.17.1 Company Overview
  • 11.17.2 Company Revenue
  • 11.17.3 Products
  • 11.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies